MedPath

宁波美舒医药科技有限公司

Ownership
-
Established
2021-04-30
Employees
-
Market Cap
-
Website

Clinical Trials

0

Active:0
Completed:0

Trial Phases

0 Phases

Drug Approvals

7

NMPA:7

Drug Approvals

Mirtazapine Tablets

Product Name
米氮平片
Approval Number
国药准字H20254247
Approval Date
May 27, 2025
NMPA

Mirtazapine Tablets

Product Name
米氮平片
Approval Number
国药准字H20254248
Approval Date
May 27, 2025
NMPA

Sitagliptin and Metformin Hydrochloride Sustained-Release tablets

Product Name
西格列汀二甲双胍缓释片
Approval Number
国药准字H20253646
Approval Date
Mar 18, 2025
NMPA

Minoxidil Liniment

Product Name
米诺地尔搽剂
Approval Number
国药准字H20244727
Approval Date
Aug 27, 2024
NMPA

Minoxidil Liniment

Product Name
米诺地尔搽剂
Approval Number
国药准字H20244728
Approval Date
Aug 27, 2024
NMPA

Sitagliptin Phosphate Tablets

Product Name
磷酸西格列汀片
Approval Number
国药准字H20233945
Approval Date
Jul 25, 2023
NMPA

Olmesartan Medoxomil and Hydrochlorothiazide Tablets

Product Name
奥美沙坦酯氢氯噻嗪片
Approval Number
国药准字H20233037
Approval Date
Jan 10, 2023
NMPA

Clinical Trials

No trials found

News

No news found

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.